SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
______________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) – March 22, 2005
_______________
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
________________
|
|
|
|
|
| ||
|
Pennsylvania |
|
1-8036 |
|
23-1210010 | ||
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) | ||
|
|
|
| ||||
|
101 Gordon Drive, PO Box 645, Lionville, PA |
|
19341-0645 | ||||
|
(Address of principal executive offices) |
|
(Zip Code) | ||||
610-594-2900
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or address, if changed since last report)
________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On March 22, 2005, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer and William J. Federici, Chief Financial Officer will make a presentation at the Lehman Brothers Eighth Annual Global Healthcare Conference in Miami, FL on March 31, 2005.
A copy of the Company’s presentation from the conference will be available through the Investor link at the Company’s website, http.//www.westpharma.com. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statement and Exhibits
|
(c) |
Exhibits |
|
|
|
|
|
|
|
|
|
Exhibit # |
|
Description |
|
|
99.1 |
|
West Pharmaceutical Services, Inc. Press Release, dated March 22, 2005. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WEST PHARMACEUTICAL SERVICES, INC. |
|
|
|
/s/ Joseph E. Abbott |
|
Joseph E. Abbott |
|
Vice President and Corporate Controller |
March 29, 2005